Pharsight

1. Arymo Er patents expiration

Drug Patent Number	Company	Drug Patent Title	Drug Patent Expiry
These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US9044402	ZYLA	Abuse-deterrent pharmaceutical compositions for controlled release	Jul, 2033 (9 years from now)
US9549899	ZYLA	Abuse deterrent pharmaceutical compositions for controlled release	Jul, 2033 (9 years from now)

Drugs and Companies using MORPHINE SULFATE ingredient

Market Authorisation Date: 09 January, 2017

Treatment: Management of pain severe enough to require daily, around-the-clock, long-term opioid treatment and for which alternative treatment options are inadequate

Dosage: TABLET, EXTENDED RELEASE;ORAL

Strength	Submission Date	ANDA(s) Filed	First applicant approval	Last patent expiry	180 day status
15 mg, 30 mg and 60 mg	29 Dec, 2017	1		25 Nov, 2017	Extinguished

Strength	Dosage	Availability
60MG	TABLET, EXTENDED RELEASE;ORAL	Discontinued
30MG	TABLET, EXTENDED RELEASE;ORAL	Discontinued
15MG	TABLET, EXTENDED RELEASE;ORAL	Discontinued

ARYMO ER family patents

2. Oxaydo patents expiration

Drug Patent Number	Company	Drug Patent Title	Drug Patent Expiry
These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US7510726	ZYLA	Methods and compositions for deterring abuse of opioid containing dosage forms	Nov, 2023 (4 months ago)
US7981439	ZYLA	Methods and compositions for deterring abuse of drugs susceptible to abuse and dosage forms thereof	Nov, 2023 (4 months ago)
US8637540	ZYLA	Compositions for deterring abuse of opioid containing dosage forms	Nov, 2023 (4 months ago)
US8409616	ZYLA	Extended release opioid abuse deterrent compositions and methods of making same	Nov, 2023 (4 months ago)
US9492443	ZYLA	Abuse deterrent compositions and methods of making same	May, 2024 (a month from now)
US7201920	ZYLA	Methods and compositions for deterring abuse of opioid containing dosage forms	Mar, 2025 (10 months from now)

Drugs and Companies using OXYCODONE HYDROCHLORIDE ingredient

Market Authorisation Date: 17 June, 2011

Treatment: NA

Dosage: TABLET;ORAL

Strength	Submission Date	ANDA(s) Filed	First applicant approval	Last patent expiry	180 day status
5 mg and 7.5 mg	07 Feb, 2012	1		16 Mar, 2025	Extinguished

Strength	Dosage	Availability
7.5MG	TABLET;ORAL	Discontinued
5MG	TABLET;ORAL	Discontinued

OXAYDO family patents

3. Sprix patents expiration

Drug Patent Number	Company	Drug Patent Title	Drug Patent Expiry
These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US7476689	ZYLA	Therapeutic compositions for intranasal administration which include KETOROLAC	Oct, 2012 (11 years ago)
US6333044	ZYLA	Therapeutic compositions for intranasal administration which include KETOROLAC®	Dec, 2018 (5 years ago)

Drug Exclusivity	Drug Exclusivity Expiration
New Dosage Form(NDF)	May 14, 2013

Drugs and Companies using KETOROLAC TROMETHAMINE ingredient

Market Authorisation Date: 14 May, 2010

Treatment: Treatment of pain using a nasal spray of ketorolac tromethamine; Treatment of inflammation and pain using a nasal spray of ketorolac tromethamine

Dosage: SPRAY, METERED;NASAL

Strength	Submission Date	ANDA(s) Filed	First applicant approval	Last patent expiry	180 day status
15.75 mg/spray	12 Mar, 2012	1		25 Dec, 2018	Extinguished

Strength	Dosage	Availability
15.75MG/SPRAY	SPRAY, METERED;NASAL	Prescription

SPRIX family patents

4. Zorvolex patents expiration

Patent	Proceeding Filing Date	Status	Respondent	Petitioner

US8999387	December, 2015	Terminated-Denied	iCeutica Pty Ltd.	Lupin Pharmaceuticals, Inc.
US9017721	December, 2015	Terminated-Denied	iCeutica Pty Ltd.	Lupin Pharmaceuticals, Inc.

Drug Patent Number	Company	Drug Patent Title	Drug Patent Expiry
These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US9017721	ZYLA	Formulation of diclofenac	Apr, 2030 (6 years from now)
US9180095	ZYLA	Formulation of diclofenac	Apr, 2030 (6 years from now)
US9180096	ZYLA	Formulation of diclofenac	Apr, 2030 (6 years from now)
US9173854	ZYLA	Formulation of diclofenac	Apr, 2030 (6 years from now)
US9186328	ZYLA	Formulation of diclofenac	Apr, 2030 (6 years from now)
US8999387	ZYLA	Formulation of diclofenac	Apr, 2030 (6 years from now)
US8679544	ZYLA	Formulation of diclofenac	Apr, 2030 (6 years from now)

Drug Exclusivity	Drug Exclusivity Expiration
New Indication(I-692)	Aug 22, 2017
New Product(NP)	Oct 18, 2016

Drugs and Companies using DICLOFENAC ingredient

Market Authorisation Date: 18 October, 2013

Treatment: Treatment of pain

Dosage: CAPSULE;ORAL